FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:71-72 July 6, 2000 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

To the Editor: Schmidt et al. (Feb. 10 issue)¹ credit foscarnet therapy with the favorable outcome in a patient infected with the human immunodeficiency virus (HIV) who had Epstein–Barr virus (EBV)–associated polyclonal B-cell lymphoproliferation. This interpretation is surprising, since the use of highly active antiretroviral therapy is more likely to account for the tumor regression. The patient had received highly active antiretroviral therapy (zidovudine, lamivudine, and saquinavir) for only four weeks before presentation and started highly active antiretroviral therapy with four drugs (stavudine, lamivudine, saquinavir, and ritonavir) after a break of just one week. This treatment was effective, reducing the . . . [Full Text of this Article]

References

Related Letters:

Virostatic Therapy for Advanced Lymphoproliferation Associated with the Epstein–Barr Virus in an HIV-Infected Patient
Schmidt W., Anagnostopoulos I., Scherübl H.
Extract | Full Text  
N Engl J Med 2000; 342:440-441, Feb 10, 2000. Correspondence

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.